COVID-19 treatment: AYUSH 64 found effective to treat mild to moderate infections

sars-cov-2
sars-cov-2 virus

Amid devastating second wave of COVID-19 in India, the scientists of reputed research institutions have found that AYUSH 64, a poly herbal formulation, is useful in the treatment of asymptomatic, mild and moderate COVID-19 infections.

Developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), AYUSH 64 comprises Alstonia scholaris (aqueous bark extract), Picrorhiza kurroa (aqueous rhizome extract), Swertia chirata (aqueous extract of whole plant) and Caesalpinia crista (fine-powdered seed pulp). 

It is extensively studied, scientifically developed, safe and effective Ayurveda formulation. This medicine is also recommended in National Clinical Management Protocol based on Ayurveda and Yoga which is vetted by National Task Force on COVID-19 Management of ICMR, the ministry of AYUSH said in a press release. Also Read: Bharat Biotech’s Covaxin found to neutralize 617 variants of COVID-19

Dr Arvind Chopra, Director, Centre for Rheumatic Diseases, Pune and honorary chief clinical coordinator of the Ministry of Ayush – CSIR collaboration said that AYUSH 64 as an adjunct to standard of care (SoC) showed significant improvement and thus lesser period of hospitalization as compared SoC alone. 

He added that controlled drug trial study of the drug has provided substantial evidence that AYUSH 64 can be effectively and safely used to treat mild to moderate cases of COVID-19 as adjuvant to SoC. He also added that, patients on AYUSH 64 will still require monitoring so as to identify any worsening of disease requiring more intensive therapy with oxygen and other treatment measures provided during hospitalization. 

Dr. N. Srikanth, Director General, CCRAS elaborated that additional studies on Ayush 64 are underway at various reputed research institutes including CSIR-IIIM, DBT-THSTI, ICMR-NIN, AIIMS Jodhpur among others.  He added that the outcome of the seven clinical studies has revealed that AYUSH 64 exhibits early clinical recovery in COVID-19 cases without further progression. In all clinical studies, AYUSH 64 was found to be well tolerated and found clinically safe.  Also Read: Vaccination is a weapon to control pandemic: Dr Shekhar Salkar

LEAVE A REPLY

Please enter your comment!
Please enter your name here